Oncotarget

Research Papers:

Preoperative prediction of hepatocellular carcinoma with portal vein tumor thrombus based on conventional data

Pengpeng Zhu, Yan Liao, Jiyuan Fan, Xin Li, Lili Su, Jun Li, Shengguang Yuan, Junxiong Yu and Weijia Liao _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:104227-104237. https://doi.org/10.18632/oncotarget.22198

Metrics: PDF 1238 views  |   HTML 2185 views  |   ?  


Abstract

Pengpeng Zhu1,*, Yan Liao1,2,*, Jiyuan Fan1,*, Xin Li3, Lili Su4, Jun Li1, Shengguang Yuan5, Junxiong Yu6 and Weijia Liao1

1Laboratory of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, P.R. China

2Disease Prevention and Control Center of Guilin, Guilin, Guangxi, P.R. China

3Department of Pathology and Pathophysiology, Xiangya hospital, Central South University, Changsha, P.R. China

4Department of Clinical Laboratory, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, Guangxi, P.R. China

5Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, P.R. China

6Department of Anesthesiology, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, P.R. China

*These authors have contributed equally to this work

Correspondence to:

Weijia Liao, email: [email protected]

Junxiong Yu, email: [email protected]

Shengguang Yuan, email: [email protected]

Keywords: hepatocellular carcinoma; portal vein tumor thrombosis; prediction; clinical index; survival

Received: July 14, 2017    Accepted: September 20, 2017    Published: October 31, 2017

ABSTRACT

Hepatocellular carcinoma (HCC) has a high predilection with portal vein tumor thrombosis (PVTT). However, part of the PVTT type can be found only under the microscopy, which was namely as type I0. The objective of this study was to establish a simple and inexpensive non-invasive model to predict the presentation of PVTT at HCC patients. A total of 815 HCC patients were retrospectively evaluated and randomly assigned into 2 groups: the training group (n = 408) and validation group (n = 407). A new index model, namely WγAL, was built to predict the presence of PVTT in the training subjects and was further validated in the validation subjects. At the optimal cutoff of 8.90, WγAL identified patients with a hazard ratio (HR) of 7.139 for the presence of PVTT. The area under receiver operating characteristic (AUROC) of WγAL was 0.795 (sensitivity: 71.9%; specificity: 78.6%) for differentiation between PVTT and non-PVTT patients in the training group. The AUROC of WγAL in differentiating patients with PVTT type I0 from non-PVTT patients was 0.748 (sensitivity: 72.1%; specificity: 68.4%) with an HR of 5.355. In addition, WγAL > 8.90 was significantly associated with large tumors, multiple tumor numbers, TNM stage III-IV, metastasis, and overall survival in HCC patients. The novel predictive model represents a simple and inexpensive model that can identify the presence of PVTT in HCC patients with a high degree of accuracy, with important clinical significance in the future therapeutic management of HCC patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22198